TABLE 2.
Susceptibility testing and β-lactamase characterization in clinical isolates of A. baumannii
| MICs (μg/mL) |
Acquired β-lactamases | ADC type | Relative expression |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Isolate | ST | Ceftazidime | Meropenem | Cefiderocol | Cefiderocol + avibactam (4 μg/mL) | bla ADC | bla oxa-51-type | ||
| ATCC 19606 | 8 | 1 | ≤ 0.03 | ≤ 0.03 | 1 | 1 | |||
| D13 | 250 | 8 | > 16 | 0.25 | 0.25 | TEM-1 | NAa | ↓ | ↑ |
| D1 | 250 | > 32 | > 16 | 1 | 1 | SHV-12, OXA-23 | ADC25 | ↔ | ↔ |
| S15 | 229 | > 32 | > 16 | 4 | 2 | OXA-24 | ADC33 | ↑ | ↑ |
| K47 | 229 | > 32 | > 16 | 16 | 8 | SHV-5 | ADC25 | ↑ | ↑ |
| S6 | 229 | > 32 | > 16 | 16 | 2 | SHV-5 | ADC25 | ↑ | ↑ |
| W7 | 229 | > 32 | > 16 | 16 | 4 | SHV-5 | ADC25 | ↑ | ↑ |
| W315 | 229 | > 32 | 8 | 64 | 2 | SHV-5 | ADC25 | ↑ | ↑ |
| D103 | 229 | > 32 | 16 | > 64 | 4 | SHV-5 | NA | ↑ | ↑ |
| E27 | 2 | > 32 | > 16 | 2 | 0.25 | TEM-1, SHV-12 | ADC30 | ↑ | ↑ |
| A53 | 2 | > 32 | > 16 | 8 | 4 | OXA-24 | ADC33 | ↑ | ↑ |
| L301 | 2 | > 32 | 16 | 16 | 2 | TEM-1, SHV-5 | ADC25 | ↑ | ↑ |
| U20 | 2 | > 32 | 16 | 16 | 4 | None | ADC33 | ↑ | ↑ |
| D501 | 2 | > 32 | 8 | 32 | 4 | TEM-1, SHV-5 | ADC33 | ↑ | ↑ |
| C120 | 2 | > 32 | > 16 | 32 | 4 | TEM-1, SHV-5 | ADC25 | ↑ | ↑ |
| H13 | 2 | > 32 | > 16 | 64 | 1 | SHV-5 | ADC25 | ↑ | ↑ |
| A8 | 2 | > 32 | > 16 | > 64 | 4 | OXA-23 | ADC33 | ↑ | ↑ |
a
No amplification.